MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma

Leukemia Research

Volumn 39, Issue 6, 2015, Pages 632-637

  Shepshelovich, Daniel ^a,d   Ram, Ron ^b,d   Uziel, Orit ^a,d   Kushnir, Michal ^c   Lithwick Yanai, Gila ^c   Hoshen, Moshe ^c   Feinmesser, Meora ^a,d   Bairey, Osnat ^a,d   Lahav, Meir ^a,d  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c ROSETTA GENOMICS LTD   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Lymphoma; MicroRNA; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MICRORNA; PREDNISONE; VINCRISTINE SULFATE; RNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TERTIARY CARE CENTER; TUMOR BIOPSY; VALIDATION PROCESS; BIOPSY; BIOSYNTHESIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84929509776     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.03.018     Document Type: Article

References (50)

1. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
2. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
3. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
4. Bea S., Zettl A., Wright G., et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005, 106:3183-3190.
5. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
6. Xi Y., Nakajima G., Gavin E., et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13:1668-1674.
7. Alencar A.J., Malumbres R., Kozloski G.A., et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011, 17:4125-4135.
8. Malumbres R., Sarosiek K.A., Cubedo E., et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009, 113:3754-3764.
9. Montes-Moreno S., Martinez N., Sanchez-Espiridion B., et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011, 118:1034-1040.
10. Eis P.S., Tam W., Sun L., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005, 102:3627-3632.
11. Lawrie C.H., Chi J., Taylor S., et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009, 13:1248-1260.
12. Culpin R.E., Proctor S.J., Angus B., et al. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol 2010, 37:367-376.
13. Zhang J., Jima D.D., Jacobs C., et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113:4586-4594.
14. Roehle A., Hoefig K.P., Repsilber D., et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008, 142:732-744.
15. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, Lyon, IARC Press.
16. Brenner B., Hoshen M.B., Purim O., et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011, 17:3976-3985.
17. Rosenfeld N., Aharonov R., Meiri E., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26:462-469.
18. Lebanony D., Benjamin H., Gilad S., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27:2030-2037.
19. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995, 57:289-300.
20. Lawrie C.H., Soneji S., Marafioti T., et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007, 121:1156-1161.
21. Dagan L.N., Jiang X., Bhatt S., et al. miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood 2012, 119:513-520.
22. Grady W.M., Parkin R.K., Mitchell P.S., et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008, 27:3880-3888.
23. Guglielmelli P., Tozzi L., Pancrazzi A., et al. MPD Research Consortium. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 2007, 35:1708-1718.
24. Bruchova H., Merkerova M., Prchal J.T. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008, 93:1009-1016.
25. De Marchis M.L., Ballarino M., Salvatori B., et al. A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. Leukemia 2009, 23:856-862.
26. Ronchetti D., Lionetti M., Mosca L., et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics 2008, 1:37.
27. Lenze D., Leoncini L., Hummel M., et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011, 25:1869-1876.
28. Cittelly D.M., Das P.M., Spoelstra N.S., et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010, 9:317.
29. Krause M., Dent E.W., Bear J.E., et al. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 2003, 19:541-564.
30. Ballabio E., Mitchell T., van Kester M.S., et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010, 116:1105-1113.
31. Wang H., Wu J., Meng X., et al. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis 2011, 32:1033-1042.
32. Merkerova M., Belickova M., Bruchova H. Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 2008, 81:304-310.
33. Tan L.P., Wang M., Robertus J.L., et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest 2009, 89:708-716.
34. Yang C., Wang C., Chen X., et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 2013, 132:116-127.
35. Sun Y., Su B., Zhang P., et al. Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. Oncol Rep 2013, 29:704-712.
36. Dettmer M.S., Perren A., Moch H., et al. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol 2014, 52:181-189.
37. Munshi S.U., Panda H., Holla P., et al. MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. PLoS ONE 2014, 9:e95920.
38. Hsu A., Chen S.J., Chang Y.S., et al. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int 2014, 418628.
39. Vasilescu C., Rossi S., Shimizu M., et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS ONE 2009, 4:e7405.
40. Fayyad-Kazan H., Bitar N., Najar M., et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 2013, 11:31.
41. Ziepert M., Hasenclever D., Kuhnt E., et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:2373-2380.
42. Lenz G., Staudt L.M. Aggressive lymphomas. N Engl J Med 2010, 362:1417-1429.
43. Ji J., Shi J., Budhu A., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
44. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
45. Yanaihara N., Caplen N., Bowman E., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
46. Schetter A.J., Leung S.Y., Sohn J.J., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
47. Calin G.A., Ferracin M., Cimmino A., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
48. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
49. Maurer M.J., Ghesquières H., Jais J.P., et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014, 32:1066-1073.
50. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775-789.